Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Phase 1

Recruiting

Conditions: FSGS
SLE Nephritis
SIOD
Cystinosis
CKD Stage 4

Interventions: Drug: Cyclophosphamide 1200 mg/Kg
Drug: Cyclophosphamide 100 mg/Kg
Drug: Fludarabine
Radiation: Total Body Irradiation
Drug: ATG
Drug: Rituximab
Device: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System
Drug: Melphalan
Procedure: Kidney Transplant

First Posted Date: 2022-08-19

Last Posted Date: 2023-07-17

Lead Sponsor: Alice Bertaina

Target Recruit Count: 12

Registration Number: NCT05508009

Locations: 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Phase 2

Recruiting

Conditions: Group D Retinoblastoma
Bilateral Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma
Childhood Intraocular Retinoblastoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Etoposide
Procedure: Examination Under Anesthesia
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Procedure: Ultrasound Biomicroscopy
Drug: Vincristine

First Posted Date: 2022-08-17

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 26

Registration Number: NCT05504291

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Phase 3

Recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell

Interventions: Drug: Chidamide
Drug: Carmustine
Drug: Cladribine
Drug: Etoposide
Drug: Gemcitabine
Drug: Cytarabine
Drug: Busulfan
Drug: Melphalan
Procedure: Autologous hematopoietic stem cell transplant

First Posted Date: 2022-07-20

Last Posted Date: 2022-07-25

Lead Sponsor: Sichuan University

Target Recruit Count: 306

Registration Number: NCT05466318

Locations: 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳
People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China

and more 8 locations

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

First Posted Date: 2022-07-14

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 435

Registration Number: NCT05457556

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 59 locations

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Melphalan
Drug: Sirolimus
Radiation: Total Body Irradiation (TBI)
Drug: Cyclophosphamide
Drug: Mycophenolate Mofeti
Drug: Fludarabine
Procedure: Allogeneic HSCT
Drug: Mesna
Drug: Filgrastim

First Posted Date: 2022-06-29

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 260

Registration Number: NCT05436418

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
City of Hope, Duarte, California, United States

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2

Not yet recruiting

Conditions: Neuroblastoma

Interventions: Drug: Anti Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclophosphamide injection
Drug: Topotecan
Drug: Melphalan
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Methotrexate

First Posted Date: 2022-03-31

Last Posted Date: 2022-07-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 64

Registration Number: NCT05303727

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Withdrawn

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Biological: Loncastuximab Tesirine
Drug: Melphalan

First Posted Date: 2022-02-08

Last Posted Date: 2023-01-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT05228249

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Basiliximab
Drug: Fludarabine Phosphate
Drug: Indium In 111-DOTA-Basiliximab
Drug: Melphalan
Biological: Palifermin
Radiation: Total Lymphoid Irradiation
Radiation: Total Marrow Irradiation
Biological: Yttrium Y 90 Basiliximab

First Posted Date: 2021-12-01

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 12

Registration Number: NCT05139004

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Phase 1

Active, not recruiting

Conditions: Myeloid Malignancies
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Mesna
Drug: Fludarabine phosphate
Drug: Cyclophosphamide
Drug: Melphalan
Drug: Filgrastim
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Drug: Total Body Irradiation One Dose

First Posted Date: 2021-11-10

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05115630

Locations: 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Phase 1

Recruiting

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT)
Advanced Hematologic Malignancies
Acute Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorders

Interventions: Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC
Drug: Fludarabine
Drug: Tacrolimus
Drug: Melphalan
Device: CliniMACS CD34 Reagent System
Drug: Plerixafor
Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil (MMF)
Drug: Ruxolitinib

First Posted Date: 2021-10-21

Last Posted Date: 2024-02-20

Lead Sponsor: Stanford University

Target Recruit Count: 40

Registration Number: NCT05088356

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy